Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chorionic gonadotropin subunit beta 1 (CGB1) is one of several highly homologous genes that encode the beta subunit of human chorionic gonadotropin (hCG), a glycoprotein hormone critical for the maintenance of pregnancy[1][2][4][6]. However, the CGB1 gene is atypical within this family: although transcripts from CGB1 have been detected in vivo and shown to associate with polysomes—suggesting potential for translation—a bona fide CGB1 protein product has not been identified or isolated to date[1][2]. Additionally, the hypothetical protein encoded by the canonical CGB1 open reading frame does not share significant similarity with the functional hCG beta subunit, due to a frameshift mutation that alters the protein sequence[1][2]. Only a subset of CGB genes (typically CGB, CGB5, CGB7, CGB8) encode the functional beta subunit of hCG; CGB1 and CGB2 were long considered pseudogenes, and their biological relevance is unclear[2]. Although CGB1 transcript expression has been reported in some cancers, including ovarian cancer, there is little evidence for a biologically active protein or a defined role as a drug target, biomarker, or mediator of disease or normal physiology[4]. CGB1 is not a recognized drug target, receptor, enzyme, transporter, or signaling protein according to current knowledge and major annotation resources[1][6]. It should not be conflated with the functional hCG beta subunit (encoded by CGB, CGB5, etc.), which has established physiological and clinical significance. There is no evidence of drugs interacting with CGB1, nor any mechanism of action, pharmacodynamic biomarkers, or safety concerns specific to this gene or hypothetical protein. Due to the lack of confirmed protein product or physiological function, and historical misclassification as a pseudogene, CGB1 should not be considered a viable or canonical therapeutic target or biomarker[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chorionic gonadotropin subunit beta 1 (CGB1).